Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Liabilities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Total Liabilities for 12 consecutive years, with $22.0 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Total Liabilities fell 80.07% year-over-year to $22.0 million, compared with a TTM value of $22.0 million through Jun 2025, down 80.07%, and an annual FY2024 reading of $17.7 million, up 29.3% over the prior year.
  • Total Liabilities was $22.0 million for Q2 2025 at Avalo Therapeutics, up from $15.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $224.8 million in Q1 2024 and bottomed at $13.7 million in Q4 2023.
  • Average Total Liabilities over 5 years is $51.7 million, with a median of $40.5 million recorded in 2021.
  • The sharpest move saw Total Liabilities soared 428.95% in 2024, then crashed 92.92% in 2025.
  • Year by year, Total Liabilities stood at $57.1 million in 2021, then decreased by 22.49% to $44.3 million in 2022, then tumbled by 69.09% to $13.7 million in 2023, then rose by 29.3% to $17.7 million in 2024, then increased by 24.34% to $22.0 million in 2025.
  • Business Quant data shows Total Liabilities for AVTX at $22.0 million in Q2 2025, $15.9 million in Q1 2025, and $17.7 million in Q4 2024.